

Zinc Supplementation for Promoting Growth in Children Under 5 years of age in Low- and Middle-income Countries: A Systematic Review

TARUN GERA¹, DHEERAJ SHAH² AND HARSHPAL SINGH SACHDEV³

From Departments of Pediatrics, ¹SL Jain Hospital and ²University College of Medical Sciences (University of Delhi) and GTB Hospital; and ³Department of Pediatrics and Clinical Epidemiology, Sitaram Bhartia Institute of Science and Research; New Delhi, India.

Correspondence to: Dr Harshpal Singh Sachdev, Senior Consultant, Department of Pediatrics and Clinical Epidemiology, Sitaram Bhartia Institute of Science and Research, New Delhi, India. hpssachdev@gmail.com

Received: September 10, 2018; Initial review: October 29, 2018; Accepted: February 21, 2019.

Objective: To study the effect of zinc supplementation in children under 5 years of age from low- and middle-income countries (LMICs) on anthropometry and prevalence of malnutrition.

Design: Systematic review of randomized controlled trials and cluster randomized trials.

Setting: Low- and middle-income countries.

Participants: 63 trials with zinc supplementation, incorporating data on 27372 children. Trials conducted exclusively in specifically diseased participants and in children with severe acute malnutrition were excluded.

Intervention: Zinc supplementation, provided either as medicinal supplementation or through food fortification.

Outcome Measures: (i) Anthropometry: weight, height, weight-for-height, mid-arm circumference, head circumference; (ii) Prevalence of malnutrition.

Results: There was no evidence of effect on height-for-age Z score at the end of supplementation period (25 trials; 9165 participants; MD= 0.00 Z; 95% CI -0.07, 0.07; $P=0.98$; moderate quality evidence) with significant heterogeneity ($I^2 = 57%$; $P<0.001$) related to dose and duration of zinc between trials. There was little or no effect on change in height-for-age Z score (13 trials; 8852 participants; MD= 0.11 Z; 95% CI -0.00, 0.21; $P=0.05$), but the heterogeneity was considerable ($I^2=94%$; $P<0.001$). There was no evidence of effect on length (6303 participants; MD= 1.18 cm; 95% CI -0.63, 2.99 cm, $P=0.20$; moderate quality evidence; considerable heterogeneity, $I^2=99%$) but a little positive effect on change in length (19 trials; 10783 participants; MD= 0.43 cm; 95% CI 0.16, 0.70, $P=0.002$; moderate quality evidence; considerable heterogeneity, $I^2=93%$). There was no evidence of effect on weight-for-age Z score or change in weight-for-age Z score but a little positive effect on weight (19 trials; 8851 study participants; MD= 0.23 kg; 95% CI 0.03, 0.42; $P=0.02$; considerable heterogeneity, $I^2=91%$) and change in weight (kg) (23 trials; 10143 study participants; MD= 0.11 kg; 95% CI 0.05, 0.17, $P<0.001$, substantial heterogeneity, $I^2=80%$). There was no evidence of effect on weight-for-height Z score, and mid upper arm circumference at the end of supplementation period, but there was a little positive effect on change in mid-arm circumference from baseline (8 trials; 1724 participants; MD = 0.09 cm; 95% CI 0.01, 0.16; $P=0.03$; no heterogeneity, $I^2=0%$). Head circumference in zinc supplemented group was marginally higher compared to control (2966 study participants; MD= 0.39 cm; 95% CI 0.03, 0.75; $P=0.03$; substantial heterogeneity, $I^2=67%$). There was no evidence of benefit in stunting (10 trials; 11838 study participants; RR= 1.0; 95% CI 0.95, 1.06; $P=0.89$; moderate quality evidence; no significant heterogeneity, $I^2=11%$), wasting (7 trials; 8988 study participants; RR= 0.94; 95% CI 0.82, 1.06; $P=0.31$; moderate quality evidence; no significant heterogeneity, $I^2=13%$) or underweight (7 trials; 8677 study participants; RR= 1.08; 95% CI 0.96, 1.21; $P=0.19$; moderate quality evidence; substantial heterogeneity, $I^2=73%$).

Conclusion: Available evidence suggests that zinc supplementation probably leads to little or no improvement in anthropometric indices and malnutrition (stunting, underweight and wasting) in children under five years of age in LMICs. Advocating zinc supplementation as a public health measure to improve growth, therefore, appears unjustified in these settings with scarce resources.

Keywords: Health interventions, Micronutrient supplementation, Protein energy malnutrition, Stunting, Wasting.

Published online: March 17, 2019. PII:S097475591600129

Accompanying Editorial: Pages 363-64

Zinc-responsive deficits in body composition are widespread in low- and middle-income countries (LMICs), particularly in South East Asia and sub-Saharan Africa, mainly because of inadequate dietary zinc intakes [1], high consumption of cereal-based foods having inhibitors of zinc absorption, and fecal losses of zinc due to recurrent episodes of diarrhea. Zinc plays a critical role in the cellular growth and differentiation due to its direct impact

on nucleic acid and protein synthesis [2], and hormonal mediators of growth [3]; and its effects on appetite [4] and risk of infection [5]. Zinc deficiency is believed to be an important cause of childhood stunting, up to the extent that it is often considered as a marker of prevalence of zinc deficiency in the communities.

Multiple studies have been carried out to assess the effect of zinc supplementation on children's growth. The results of these studies are inconsistent, and the factors responsible for these varied outcomes are unknown. In the published systematic reviews on the topic [6,7], there is considerable variability in terms of participants, nature of interventions, choice of control groups, study setting, and other key variables. It is thus difficult to provide unambiguous evidence-based advice to policy makers in LMICs about the safety and benefits of investing in zinc supplementation programs to improve linear growth in under-five children. An updated systematic review, primarily focused on LMICs, may be helpful in crystalizing relevant policy. We conducted this systematic review to study the effect of zinc supplementation on growth (measured by anthropometry) and prevalence of malnutrition.

METHODS

We included randomized controlled trials with variations in design, including random allocation of individuals or clusters, multi-arm trials, factorial trials and cross-over trials for the first period of measurement only. Quasi-randomized controlled trials (individual or cluster allocation done on the basis of a pseudo-random sequence; for example, odd/even, house number or date of birth, alternation) were also eligible for inclusion. We included trials conducted in children below 5 years of age from LMICs. Trials conducted exclusively in disease conditions and in children with severe acute malnutrition (SAM) were excluded

Type of Intervention

We included studies that provided zinc supplementation, either as medicinal supplementation or through food fortification. Trials with simultaneous fortification or supplementation of additional micronutrients, or simultaneous co-interventions like health education and/or drugs (for example, deworming or antimalarials) were included if the only difference between the intervention and comparison arms was zinc supplementation.

Outcomes

Primary: anthropometry: weight, height, weight-for-height (WFH), mid upper arm circumference (MUAC), head circumference; *Secondary:* prevalence of malnutrition.

Search Methods

We searched (June 2017) the following electronic databases: Medline, Web of Science, BIOSIS Previews, Greysource, Cochrane Controlled Trials Register, EMBASE and IBIDS. Reference lists of all included

papers and relevant reviews were scanned to identify citations that have been missed in the primary search. We contacted authors of other relevant reviews in the field regarding additional studies of which they may be aware. We searched Science Citation Index and Social Sciences Citation Index for papers, which cite studies included in the review. Websites of organizations like Micronutrient Initiative and iZiNCG were also searched. The search results from the various databases and other sources were merged using reference management software (Endnote) to remove duplicate records. The title and abstract of the studies identified in the computerized search were scanned in duplicate to exclude references that were obviously irrelevant. In order to determine eligibility for inclusion of the remaining articles, their full texts were reviewed, and multiple reports of the same study were linked together. Two authors independently screened and assessed the eligibility of the studies, extracted relevant data and assessed the risk of bias for all included studies. Any dispute regarding these criteria was resolved among the investigators by mutual consultation. **Web Appendix 1** outlines the search strategy adopted for the electronic databases.

Data Management

We evaluated the risk of bias for each trial using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions [8]. Plots of 'Risk of bias' assessments were created in Review Manager (RevMan) [9].

Risk ratio (RR) estimates with 95% confidence intervals (CI) were used for binary outcomes; for continuous outcomes, mean differences (MD) were used. In order to maximize the data input for the pooled outcome measures, we utilized post-intervention values (means and standard deviations (SDs)) in preference to the changes from baseline [8]. In factorial trials and in multi-arm designs yielding two or more intervention groups (different zinc doses or salts used) and a single control group, the data in the intervention groups, including the variation in the intervention characteristic, was pooled and compared against the single control group to prevent unit-of-analysis error. For cluster-randomized trials, we used the stated cluster-adjusted RR or means and 95% CI, irrespective of the method employed for adjustment. In case of missing data, we contacted trial authors for information wherever possible; and where this could not be done, or the authors did not respond, we imputed the missing values, where feasible. In case any assumptions were made for such imputations, they were recorded, and are detailed in **Web Appendix 2**.

We assessed contextual heterogeneity on the basis of

information collected on the context in which the intervention was implemented. We assessed for variability in the participants, interventions and outcomes studied to identify clinical heterogeneity, and for variability in study design to describe methodological diversity. Statistical heterogeneity was identified and measured as recommended [8]. A P value of 0.05 from the Chi^2 test was used to determine statistical significance with regard to heterogeneity.

We performed statistical analysis using the Revman software. Pooled estimates of the evaluated outcome measures were calculated by the generic inverse variance method. Pooled WMD and SMD were calculated as per standard recommendations [8]. We expected variation in studies with respect to populations, interventions, comparators, outcomes and settings, and thus used the random-effects model. If it was not possible to synthesize the data from the included studies, we provided a narrative synthesis of the results. The data were finally synthesized as a 'Summary of findings' table. For each outcome, quality assessment of the results was also carried out using the GRADE approach [10], which specifies four levels of quality (high, moderate, low and very low) where the highest quality rating is for a body of evidence based on randomized trials. We planned to explore the following differences in effect for 'length', by subgroup analyses: (i) supplementation method (medicinal *versus* fortification); (ii) supplement compound; (iii) study population from South Asia; (iv) dose of zinc (mg); (v) duration of supplementation; (vi) compliance estimation (directly observed or replacement *versus* others); (vii) baseline zinc levels; and (viii) baseline prevalence of stunting. We chose length-for-age Z-score as the variable for subgroup analysis, as it is an age-independent parameter and more important from public health perspective. We could not do the subgroup analysis for the first parameter (supplementation method) as all studies had used medicinal supplementation.

RESULTS

The search output from various databases is detailed in **Web Appendix 1**, and the results are summarized in **Fig. 1**. We screened 3886 records, of which 237 were potentially eligible. Of these, 147 references were excluded and 91 publications (63 studies) were included in the final analyses [3, 11-100]. These studies (5 cluster RCTs and 58 RCTs) incorporating data on 27372 children were included in the final analysis (**Web Table I**). Twenty-eight (44%) of the included trials were conducted in Asia (17 from South Asia), 16 trials were conducted in Africa and 19 in Latin America. The details of study location, intervention and outcomes are summarized in **Web Table I**.

Web Fig. 1 and **Web Fig. 2** summarize the Risk of Bias for the included studies. The risk of bias for the 55 trials was low for random sequence generation. It was considered to be high for two trials and unclear for the remaining six studies. The risk of bias for allocation concealment was judged to be low in 39, unclear in 21 and high in 3 studies. Blinding of participants and research personnel was at unclear risk in 5, at high risk in 2 studies and low risk in 56 trials. The risk of blinding of outcome assessment was considered low for 34 trials, unclear for 27 and high for 2 trials. The risk of bias for attrition was judged to be high for 32 trials, unclear for 2 trials because of no information available, and low for remaining 29 trials. In the five cluster randomized trials, two studies were considered to be at unclear risk for




FIG. 1 The PRISMA flow chart.

incorrect analysis and one trial for baseline imbalance. Seven trials were judged to be having other potential causes of bias, including baseline imbalance of groups (3), formula milk use (2) and protocol deviations related to key intervention (2).

Effects of Interventions

Height/Length (Web Appendix 3A): Twenty-nine trials reported data on height-for-age Z-score (HAZ) in the study participants. Quantitative synthesis from 25 trials (Fig. 2) revealed no evidence of effect of zinc supplementation on HAZ (9165 participants; MD= 0.00; 95% CI -0.07, 0.07; $P=0.98$; Moderate Quality Evidence) in comparison to controls, with significant heterogeneity between trials ($I^2 = 57%$; $P<0.001$). In subset analysis to explore heterogeneity, the dose of zinc and duration of zinc supplementation were important predictors of heterogeneity. Supplement compound, location in South Asia, compliance estimation, baseline serum zinc levels, baseline prevalence of stunting and baseline HAZ did not predict heterogeneity. Thirteen trials studied the effect of zinc supplementation on change in HAZ. On quantitative synthesis in 8852 participants, the MD for change in HAZ was 0.11 (95% CI -0.00, 0.21; $P=0.05$; Moderate Quality Evidence; Fig. 3) with substantial heterogeneity between trials ($I^2 =$

94%; $P<0.001$). Twenty-one trials reported the effect of zinc supplementation on length/height at the end of supplementation period. On quantitative synthesis from 19 trials, there was no evidence of effect on length/height (6303 participants; MD= 1.18 cm; 95% CI -0.63, 2.99 cm, $P=0.20$; Moderate Quality Evidence; considerable heterogeneity, $I^2=99%$; Fig. 4) with zinc supplementation as compared to controls. Twenty-six trials reported the effect of zinc supplementation (vs. controls) on change in length/height (cm) from baseline to the end of supplementation period. In 25 of these trials with 10783 participants, the pooled change in length/height with zinc supplementation as compared to controls was 0.43 cm (95% CI 0.16, 0.70, $P=0.002$; considerable heterogeneity, $I^2=93%$; Moderate Quality Evidence; Fig. 5). Funnel plots of all height-related outcomes showed no evidence of publication bias (Web Fig. 3a to 3d).

Weight (Web Appendix 3B): Twenty-five trials reported data on weight-for-age Z-score (WAZ) in the study participants. In 23 trials on 9033 participants (Fig. 6), the mean difference in WAZ was 0.05 (95% CI -0.03, 0.13; $P=0.19$; Moderate Quality Evidence; substantial heterogeneity, $I^2=75%$) between zinc supplemented and control group. Thirteen trials studied the effect of zinc




FIG. 2 Forest plot of effect of zinc supplementation on height-for-age Z scores.




FIG. 3 Forest plot of effect of zinc supplementation on change in height-for-age Z scores.




FIG. 4 Forest plot of effect of zinc supplementation on height/length at the end of supplementation period.

supplementation on change in WAZ from baseline. Quantitative synthesis from these trials (Fig. 7) showed no evidence of effect on change in WAZ with zinc supplementation in comparison to controls (8851 study participants; MD = 0.03; 95% CI -0.01, 0.08; P = 0.17; Moderate Quality Evidence; substantial heterogeneity, I² = 66%). Weight at the end of the supplementation period was reported in 20 studies. Quantitative synthesis from 19 of these trials (Fig. 8) showed positive effect of zinc supplementation on weight as compared to control population (8851 study participants; MD = 0.23 kg; 95%

CI 0.03, 0.42; P = 0.02; Moderate Quality Evidence). Twenty-three trials reported on change in weight (kg) from baseline to the end of supplementation period. Quantitative synthesis (Fig. 9) revealed a positive effect (10143 participants; MD = 0.11 kg; 95% CI 0.05, 0.17; P < 0.001; Moderate Quality Evidence) of zinc supplementation in comparison to controls. There was significant heterogeneity between trials comparing weight parameters between the two groups, and funnel plots showed no evidence of publication bias (figures not shown).




FIG. 5 Forest plot of effect of zinc supplementation on change in height/length.




FIG. 6 Forest plot of effect of zinc supplementation on weight-for-age Z scores.

Weight-for-height (Web Appendix 3C): In 22 trials reporting data on weight-for-height Z-score (WHZ), there was no evidence of effect of zinc supplementation on WHZ in comparison to controls (19 trials; 8392 study

participants; MD=0.03; 95% CI -0.02, 0.08; P=0.21; Moderate Quality Evidence; considerable heterogeneity, I²=91%; Fig. 10). In 12 trials evaluating the change in weight from height Z-scores, there was no evidence of




FIG. 7 Forest plot of effect of zinc supplementation on change in weight-for-age Z scores.




FIG. 8 Forest plot of effect of zinc supplementation on weight at the end of supplementation period.

effect on change in WHZ with zinc supplementation as against controls (8706 study participants; MD = 0.01; 95% CI -0.03, 0.04; $P=0.74$; Moderate Quality Evidence; substantial heterogeneity, $I^2=80\%$; **Fig. 11**). There was no evidence of publication bias on examining the funnel plots (figures not shown).

MUAC (Web Appendix 3C): In 7 trials evaluating MUAC, there was no effect of zinc supplementation (vs. controls) on MUAC (4236 participants; MD = 0.0 cm; 95% CI -0.08, 0.09; $P=0.93$; Moderate Quality Evidence) with no significant heterogeneity between trials ($I^2 = 18\%$; $P=0.29$) (**Fig. 12**). There was moderate quality evidence of little increase in the change in MUAC from baseline (8 trials; 1724 participants;

MD = 0.09 cm; 95% CI 0.01, 0.16; $P=0.03$; no heterogeneity, $I^2=0\%$) by zinc supplementation in comparison to controls (**Fig. 13**).

Head circumference (Web Appendix 3D): In quantitative synthesis from six trials (**Fig. 14**) showed higher head circumference in zinc supplemented group as against control group (2966 participants; MD = 0.39 cm; 95% CI 0.03, 0.75; $P=0.03$; Moderate Quality Evidence; substantial heterogeneity, $I^2=67\%$). However, change in head circumference was not different in the zinc supplemented and placebo groups (4 trials; 497 participants; MD = 0.26 cm; 95% CI -0.18, 0.71; $P=0.24$; Moderate Quality Evidence; substantial heterogeneity, $I^2=79\%$) (**Fig. 15**).




FIG. 9 Forest plot of effect of zinc supplementation on change in weight.




FIG. 10 Forest plot of effect of zinc supplementation on weight-for-height Z scores at the end of supplementation period.

Nutritional Status (Web Appendix 3D): In trials reporting on stunting, underweight or wasting, funnel plots did not show any evidence of publication bias (figures not shown). Quantitative synthesis from nine trials (Fig. 16) showed no effect on stunting (11838 participants; RR= 1.0; 95% CI 0.95, 1.06; P=0.89; Moderate Quality

Evidence; no significant heterogeneity, I²=11%) with zinc supplementation in comparison to controls. In 7 trials reporting on the prevalence of underweight children, quantitative synthesis (Fig. 17) showed no effect of zinc supplementation (vs. controls) on underweight (8988 participants; RR= 0.94; 95% CI 0.82, 1.06; P=0.31;




FIG. 11 Forest plot of effect of zinc supplementation on change in weight-for-height Z scores.




FIG. 12 Forest plot of effect of zinc supplementation on mid upper arm circumference at the end of supplementation period.




FIG. 13 Forest plot of effect of zinc supplementation on change in mid upper arm circumference.

Moderate Quality Evidence; substantial heterogeneity, I²=73%). Quantitative synthesis (Fig. 18) from seven trials showed no effect of zinc supplementation on wasting (8677 participants; RR= 1.08; 95% CI 0.96, 1.21; P=0.19; Moderate Quality Evidence) with no significant heterogeneity (I²=13%, P=0.33).

DISCUSSION

In this systematic review of 63 trials incorporating data on 27372 children, there was no evidence of any difference in the final length/height for age or Z scores or change in length/height-for-age Z scores at the end of the supplementation period with zinc or placebo/no




FIG. 14 Forest plot of effect of zinc supplementation on head circumference at the end of supplementation period.




FIG. 15 Forest plot of effect of zinc supplementation on change in head circumference.




FIG. 16 Forest plot of effect of zinc supplementation on stunting.




FIG. 17 Forest plot of effect of zinc supplementation on underweight.




FIG. 18 Forest plot of effect of zinc supplementation on wasting.

intervention, but studies assessing the change in length/height showed slight benefit with zinc supplementation. In addition, there was marginal increase in weight of children receiving zinc supplementation in comparison to placebo, but it did not affect weight-for-age or weight-for-height Z scores. There was a marginal positive effect on the change in MUAC from baseline. Zinc supplemented children also had a slightly higher head circumference at the end of supplementation period, but there was no evidence of effect on change in head circumference. Moreover, there was no evidence of a beneficial effect on prevalence of wasting, stunting or underweight at the end of supplementation period.

All included studies involved children under five years from LMICs. This is a population that is likely to have poor zinc nutriture and, therefore, benefit more from zinc supplementation. A large number of trials were available from varied geographical settings (28 from Asia, 16 from Africa, and 19 from Latin America), conducted in different age groups and in different population settings (ranging from tertiary level medical institutions to community studies in urban slums and rural communities). Control groups in most trials were comparable with intervention groups at baseline. Thus any observed effects, or lack thereof, in the intervention groups are more likely to be attributable to zinc supplementation. We, therefore, believe that the evidence from this review is largely applicable to real-life situations among under-five children in LMICs.

Most studies in this systematic review had a low risk of bias for key parameters, including sequence generation, allocation concealment and blinding. Also given the large number of studies available for most outcomes, the certainty of evidence is reasonable (moderate quality) for most of the important outcomes, and this review is likely to provide a good indication of the likely effect. The review was conducted by following the guidelines laid down in the Cochrane Handbook for Systematic Review [8], and

this is likely to eliminate most sources of bias and identify the remaining. In some studies, anthropometric measurements were not available as the results were either depicted only in graphs or summary statistics, which is a potential source of bias. However, this is unlikely to affect the overall direction of results as narrative synthesis from these few studies was broadly in agreement with quantitative synthesis from this systematic review.

The earliest systematic review on this topic by Brown, *et al.* [6] included 33 studies, and reported a meaningful positive effects of zinc supplementation in height-for-age Z-score and weight-for-age Z-score without significant effect on weight-for-height indices. However, this review also included older children, besides being not restricted to LMICs. Ramakrishnan, *et al.* [7] reviewed 43 trials, and reported marginal benefits in terms of change in HAZ, WAZ and WHZ. Imdad, *et al.* [101] reported a significant positive effect of zinc supplementation on height gain in the developing countries, but studies providing other micronutrients in addition to zinc were also included. Mayo-Wilson, *et al.* [102], in a review of 50 studies (including children from all countries), showed no evidence of difference in height or stunting with little increase in weight and weight-to-height ratio. A very recent systematic review [103] evaluated effect of zinc supplementation provided during antenatal period or during childhood, and reported slightly increased height, weight and weight-for-age Z-score, but no effect on height-for-age Z-score, weight-for-height Z score, stunting, underweight or wasting, with supplementation provided after birth. In comparison to this review, our review focussed on LMIC where the problem of zinc deficiency is considered a major public health problem. In comparison to the review by Liu, *et al.* [103], the present review included more trials (63 vs. 54), probably because of a wide variety of database search and inclusion of trials with shorter (<3 mo) duration of supplementation. However, these results are broadly in conformity with our findings;

marginal differences probably arise from variations in populations and analytical methods.

Evidence from this review suggests that zinc supplementation probably leads to little or no improvement in anthropometric indices and malnutrition (stunting, underweight and wasting) in children under five years of age from LMICs. Advocating zinc supplementation as a public health measure to improve growth, therefore, appears unjustified in these settings with scarce resources. Using high stunting prevalence as an indicator of population-level zinc deficiency is also questionable. However, as most studies in this review examined the effects of medicinal supplementation with zinc, effect of fortification of foods with zinc on growth needs to be evaluated in pragmatic modes. Considering other potential benefits of zinc supplementation, comprehensive evaluation of cost effectiveness, including relative effects of medicinal and fortification routes, is also desirable.

Contributors: TG: conceptualized the review, literature search, data analysis and manuscript writing; DS: literature search, data analysis and manuscript writing; HPS: conceptualized the review, data analysis and its interpretation, and critical inputs into manuscript writing.

Funding: Indian Council of Medical Research (5/7/869/2012-RCH (CH)).

Competing interests: None stated.

REFERENCES


- International Zinc Nutrition Consultative Group. Assessment of the risk of zinc deficiency in populations and options for its control. *Food Nutr Bull.* 2004;25:S91-204.
- MacDonald RS. The role of zinc in growth and cell proliferation. *J Nutr.* 2000;130:1500S-8S.
- Ninh NX, Thissen JP, Collette L, Gerard G, Khoi HH, Ketelslegers JM. Zinc supplementation increases growth and circulating insulin-like growth factor I (IGF-I) in growth-retarded Vietnamese children. *Am J Clin Nutr.* 1996;63:514-9.
- O'Dell BL, Reeves PG. Zinc status and food intake. *In: Mills CF, editor(s). Zinc in Human Biology.* Springer:Verlag, 1989. p.173-81.
- Bhutta ZA, Black RE, Brown KH, Meeks-Gardner J, Gore S, Hidayat A, *et al.* Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. *J Pediatr.* 1999;135:689-97.
- Brown KH, Peerson JM, Rivera J, Allen LH. Effect of supplemental zinc on the growth and serum zinc concentrations of prepubertal children: A meta-analysis of randomized controlled trials. *Am J Clin Nutr.* 2002;75:1062-71.
- Ramakrishnan U, Nguyen P, Martorell R. Effects of micronutrients on growth of children under 5 y of age: Meta-analyses of single and multiple nutrient interventions. *Am J Clin Nutr.* 2009;89:191-203.
- Higgins JPT, Deeks JJ. *Cochrane handbook for systematic reviews of interventions* version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
- Cochrane Community. Editorial and publishing policy resource: Review manager (RevMan). Available from: <http://community.cochrane.org/editorial-and-publishing-policy-resource/information-technology/review-manager-revman>. Accessed September 19, 2017.
- GRADEpro. GRADE's software for Summary of Findings Tables, Health Technology Assessment and Guidelines. Available from: <https://gradepro.org/>. Accessed September 19, 2017.
- Abdollahi M, Abdollahi Z, Fozouni F, Bondarianzadeh D. Oral zinc supplementation positively affects linear growth, but not weight, in children 6-24 months of age. *Int J Prev Med.* 2014;5:280-6.
- Adriani M, Wirjatmadi B. The effect of adding zinc to vitamin A on IGF-1, bone age and linear growth in stunted children. *J Trace Elements Med Biol.* 2014;28:431-5.
- Alarcon K, Kolsteren PW, Prada AM, Chian AM, Velarde RE, Pecho IL, *et al.* Effects of separate delivery of zinc or zinc and vitamin A on hemoglobin response, growth, and diarrhea in young Peruvian children receiving iron therapy for anemia. *Am J Clin Nutr.* 2004;80:1276-82.
- Aminisani N, Barak M, Shamshirgaran SM. Effect of zinc supplementation on growth of low birthweight infants aged 1-6 mo in Ardabil, Iran. *Indian J Pediatr.* 2010;78:1239-43.
- Bates CJ, Evans PH, Dardenne M, Prentice A, Lunn PG, Northrop-Clewes CA, *et al.* A trial of zinc supplementation in young rural Gambian children. *Br J Nutr.* 1993;69:243-55.
- Becquey E, Ouedraogo CT, Hess SY, Rouamba N, Prince L, Ouédraogo JB, *et al.* Comparison of preventive and therapeutic zinc supplementation in young children in Burkina Faso: A cluster-randomized, community-based trial. *J Nutr.* 2016;146:2058-66.
- Becquey E, Ouedraogo CT, Hess SY, Rouamba N, Prince L, Ouédraogo JB, *et al.* Comparison of preventive and therapeutic zinc supplementation programs for young children in Burkina Faso: A randomized, masked, community-based trial. *Faseb J.* 2013;27.
- Black MM, Sazawal S, Black RE, Khosla S, Kumar J, Menon V. Cognitive and motor development among small-for-gestational-age infants: Impact of zinc supplementation, birth weight, and caregiving practices. *Pediatrics.* 2004;113:1297-305.
- Sazawal S, Black RE, Menon VP, Dinghra P, Caulfield LE, Dinghra U, *et al.* Zinc supplementation in infants born small for gestational age reduces mortality: A prospective, randomized, controlled trial. *Pediatrics.* 2001;108:1280-6.
- Brooks WA, Santosham M, Naheed A, Goswami D, Wahed MA, Diener-West M, *et al.* Effect of weekly zinc supplements on incidence of pneumonia and diarrhoea in children younger than 2 years in an urban, low-income population in Bangladesh: randomised controlled trial. *Lancet.* 2005;366:999-1004.
- Arsenault JE, Havel PJ, de Romana DL, Penny ME, Van

- Loan MD, Brown KH. Longitudinal measures of circulating leptin and ghrelin concentrations are associated with the growth of young Peruvian children but are not affected by zinc supplementation. *Am J Clin Nutr.* 2007;86:1111-9.
22. Arsenault JE, de Romana DL, Penny ME, Van Loan MD, Brown KH. Additional zinc delivered in a liquid supplement, but not in a fortified porridge, increased fat-free mass accrual among young Peruvian children with mild-to-moderate stunting. *J Nutr.* 2008;138:108-14.
 23. Brown KH, de Romana DL, Arsenault JE, Peerson JM, Penny ME. Comparison of the effects of zinc delivered in a fortified food or a liquid supplement on the growth, morbidity, and plasma zinc concentrations of young Peruvian children. *Am J Clin Nutr.* 2007;85:538-47.
 24. Castillo-Duran C, Rodriguez A, Venegas G, Alvarez P, Icaza G. Zinc supplementation and growth of infants born small for gestational age. *J Pediatr.* 1995;127:206-11.
 25. Castillo-Durán C, Perales CG, Hertrampf ED, Marín VB, Rivera FA, Icaza G. Effect of zinc supplementation on development and growth of Chilean infants. *J Pediatr.* 2001;138:229-35.
 26. Castillo-Duran C, Hertrampf ED, Ruz MO, Torreion CS, Salazar G. Controlled trial of zinc supplementation on growth and body composition in Chilean children from low income groups. *Pediatr Res.* 2002;51:188A.
 27. Chhagan MK, den Broeck JV, Luabeya KA, Mpontshane N, Tomkins A, Bennish ML. Effect on longitudinal growth and anemia of zinc or multiple micronutrients added to vitamin A: A randomized controlled trial in children aged 6-24 months. *BMC Public Health.* 2010;10:145.
 28. Caulfield L, Zavaleta N, Chen P, Colombo J, Kannass K. Mineral status of non-anemic Peruvian infants taking an iron and copper syrup with or without zinc from 6 to 18 months of age: A randomized controlled trial. *Nutrition.* 2013;29:1336-41.
 29. Colombo J, Caulfield LE, Kannass KN, Alborno C, Lazarte F, Zavaleta N. Six months of zinc supplementation affects measures of attention in Peruvian infants at 12 months of age. *Faseb J.* 2011;25:.
 30. Colombo J, Zavaleta N, Kannas KN, Lazarte F, Alborno C, Kapa LL, *et al.* Zinc supplementation sustained normative neurodevelopment in a randomized, controlled trial of Peruvian infants aged 6–18 months. *J Nutr.* 2014;144:1298-1305.
 31. de Romana DL, Salazar M, Hambidge KM, Penny ME, Peerson JM, Krebs NF, *et al.* Longitudinal measurements of zinc absorption in Peruvian children consuming wheat products fortified with iron only or iron and 1 of 2 amounts of zinc. *Am J Clin Nutr.* 2005;81:637-47.
 32. Berger J, Ninh NX, Khan NC, Nhien NV, Lien DK, Trung NQ, *et al.* Efficacy of combined iron and zinc supplementation on micronutrient status and growth in Vietnamese infants. *Eur J Clin Nutr.* 2006;60:443-54.
 33. Dijkhuizen MA, Winichagoon P, Wieringa FT, Wasantwisut E, Utomo B, Ninh NX, *et al.* Zinc supplementation improved length growth only in anemic infants in a multi-country trial of iron and zinc supplementation in South-East Asia. *J Nutr.* 2008;238:1969-75.
 34. Pongcharoen T, DiGirolamo AM, Ramakrishnan U, Winichagoon P, Flores R, Martorell R. Long-term effects of iron and zinc supplementation during infancy on cognitive function at 9 y of age in northeast Thai children: A follow-up study. *Am J Clin Nutr.* 2011;93:636-43.
 35. Wasantwisut E, Winichagoon P, Chitchumroonchokchai C, Yamborisut U, Boonpraderm A, Pongcharoen T, *et al.* Iron and zinc supplementation improved iron and zinc status, but not physical growth, of apparently healthy, breast-fed infants in rural communities of Northeast Thailand. *J Nutr.* 2006;136:2405-11.
 36. Wieringa FT, Berger J, Dijkhuizen MA, Hidayat A, Ninh NX, Utomo B, *et al.* Combined iron and zinc supplementation in infants improved iron and zinc status, but interactions reduced efficacy in a multicountry trial in Southeast Asia. *J Nutr.* 2007;137:466-71.
 37. Dirren H, Barclay D, Ramos JG, Lozano R, Montalvo MM, Davila N, *et al.* Zinc supplementation and child growth in Ecuador. *Adv Exp Med Biol.* 1994;352:215-22.
 38. El-Farghali O, El-Wahed MA, Hassan NE, Imam S, Alian K. Early zinc supplementation and enhanced growth of the low-birth weight neonate. *Open Access Maced J Med Sci.* 2015;3:63-8.
 39. Elizabeth KE, Sreedevi P, Narayanan SN. Outcome of nutritional rehabilitation with and without zinc supplementation. *Indian Pediatr.* 2000;37:647-50.
 40. Fahmida U, Rumawas JSP, Utomo B, Patmonodewo S, Schultnik W. Zinc-iron, but not zinc-alone supplementation, increased linear growth of stunted infants with low haemoglobin. *Asia Pacific J Clin Nutr.* 2007;16:301-9.
 41. Fischer Walker CL, Baqui AH, Ahmed S, Zaman K, El Arifeen S, Begum N, *et al.* Low-dose weekly supplementation of iron and/or zinc does not affect growth among Bangladeshi infants. *Eur J Clin Nutr.* 2010;63:87-92.
 42. Gardner JMM, Powell CA, Baker-Henningham H, Walker SP, Cole TJ, Grantham-McGregor SM. Zinc supplementation and psychosocial stimulation: Effects on the development of undernourished Jamaican children. *Am J Clin Nutr.* 2005;82:399-405.
 43. Garenne M, Becher H, Ye Y, Kouyate B, Muller O. Sex-specific responses to zinc supplementation in Nouna, Burkina Faso. *J Paediatr Gastroenterol Nutr.* 2007;44:619-628.
 44. Muller O, Becher H, van Zweeden AB, Ye Y, Diallo DA, Konate AT, *et al.* Effect of zinc supplementation on malaria and other causes of morbidity in west African children: randomised double blind placebo controlled trial. *BMJ.* 2001;322:1567.
 45. Muller O, Garenne M, Rietmaier P, van Zweeden AB, Kouyate B, Becher H. Effect of zinc supplementation on growth in West African children: A randomized double-blind placebo-controlled trial in rural Burkina Faso. *Int J Epidemiol.* 2003;32:1098-102.
 46. Hershkovitz E, Printzman L, Segev Y, Levy J, Phillip M. Zinc supplementation increases the level of serum insulin-like growth factor-i but does not promote growth in infants

- with nonorganic failure to thrive. *Horm Res.* 1999;52:200-204.
47. Abbeddou S, Hess SY, Jimenez EY, Some JW, Vosti SA, Guissou RM, *et al.* Comparison of methods to assess adherence to small-quantity lipid-based nutrient supplements (SQ-LNS) and dispersible tablets among young Burkinabé children participating in a community-based intervention trial. *Maternal Child Nutr.* 2015;11(Suppl 4):90-104.
 48. Hess SY, Abbeddou S, Jimenez EY, Some JW, Vosti SA, Guissou RM, *et al.* Small-quantity lipid-based nutrient supplements, regardless of their zinc content, increase growth and reduce the prevalence of stunting and wasting in young Burkinabe children: A cluster-randomized trial. *PLoS One.* 2015;10:e0122242.
 49. Prado EL, Abbeddou S, Jimenez EY, Some JW, Ouedraogo ZP, Vosti SA, *et al.* Lipid-based nutrient supplements plus malaria and diarrhea treatment increase infant development scores in a cluster-randomized trial in Burkina Faso. *J Nutr.* 2016;146:814-22.
 50. Some JW, Abbeddou S, Yakes Jimenez E, Hess SY, Ouédraogo ZP, Guissou RM, *et al.* Effect of zinc added to a daily small-quantity lipid-based nutrient supplement on diarrhoea, malaria, fever and respiratory infections in young children in rural Burkina Faso: a cluster randomised trial. *BMJ Open.* 2015;5:e007828.
 51. Hong ZY, Zhang YW, Xu JD, Zhou JD, Gao XL, Liu XG, *et al.* Growth promoting effect of zinc supplementation in infants of high-risk pregnancies. *Chin Med J (Engl).* 1992;105:844-8.
 52. Islam MN, Chowdhury M, Siddika M, Qurishi SB, Bhuyian MKJ, Hoque MM, *et al.* Effect of oral zinc supplementation on the growth of preterm infants. *Indian Pediatr.* 2010;47:845-49.
 53. Lind T, Lönnerdal B, Stenlund H, Gamayanti IL, Ismail D, Seswandhana R, *et al.* A community-based randomized controlled trial of iron and zinc supplementation in Indonesian infants: effects on growth and development. *Am J Clin Nutr.* 2004;80:729-36.
 54. Ashworth A, Morris SS, Lira PIC, Grantham-McGregor SM. Zinc supplementation, mental development and behaviour in low birth weight term infants in northeast Brazil. *Eur J Clin Nutr.* 1998;52:223-7.
 55. Lira PIC, Ashworth A, Morris SS. Effect of zinc supplementation on the morbidity, immune function, and growth of low-birth-weight, full-term infants in northeast Brazil. *Am J Clin Nutr.* 1998;68:418S-24S.
 56. Locks L, Manji K, McDonald C, Kupka R, Kisenge R, Aboud S, *et al.* Effect of zinc & multiple micronutrient supplements on growth in Tanzanian children. *Faseb J.* 2015;29.
 57. Locks LM, Manji KP, McDonald CM, Kupka R, Kisenge R, Aboud S, *et al.* Effect of zinc and multivitamin supplementation on the growth of Tanzanian children aged 6–84 wk: A randomized, placebo-controlled, double-blind trial. *Am J Clin Nutr.* 2016;103:910-8.
 58. Long KZ, Montoya Y, Hertzmark E, Santos JI, Rosado JL. A double-blind, randomized, clinical trial of the effect of vitamin A and zinc supplementation on diarrheal disease and respiratory tract infections in children in Mexico City, Mexico. *Am J Clin Nutr.* 2006;83:693-700.
 59. Long KZ, Rosado JL, Montoya Y, Solano ML, Hertzmark E, Dupont HL, *et al.* Effect of Vitamin A and zinc supplementation on gastrointestinal parasitic infections among Mexican children. *Pediatrics.* 2007;120:e846-855.
 60. Makonnen B, Venter A, Joubert G. A Randomized Controlled Study of the Impact of Dietary Zinc Supplementation in the Management of Children with Protein–Energy Malnutrition in Lesotho. I: Mortality and Morbidity. *J Trop Pediatr.* 2003;49:340-52.
 61. Makonnen B, Venter A, Joubert G. A randomized controlled study of the impact of dietary zinc supplementation in the management of children with protein-energy malnutrition in Lesotho. II: Special investigations. *J Trop Pediatr.* 2003;49:353-60.
 62. Mathur NB, Agarwal DK. Zinc supplementation in preterm neonates and neurological development: a randomized controlled trial. *Indian Pediatr.* 2015;52:951-55.
 63. Meeks Gardner JM, Witter MM, Ramdath DD. Zinc supplementation: effects on the growth and morbidity of undernourished Jamaican children. *Eur J Clin Nutr.* 1998;52:34-39.
 64. Mozaraffi-Khosravi H, Shakiba M, Eftekhari M, Fatehi F. Effects of zinc supplementation on physical growth in 2-5-year-old children. *Biol Trac Elem Res.* 2009;128:118-27.
 65. Olney DK, Kariger PK, Stoltzfus RJ, Khalfan SS, ALi NS, Tielsch JM, *et al.* Developmental effects of micronutrient supplementation and malaria in Zanzibari children. *Early Human Dev.* 2013;89:667-74.
 66. Olney DK, Pollitt E, Kariger PK, Khalfan SS, Ali NS, Tielsch JM, *et al.* Combined iron and folic acid supplementation with or without zinc reduces time to walk in gun assisted among zanzibari infants 5- to 11-mo old. *J Nutr.* 2006;136:2427-34.
 67. Hamadani JD, Fuchs GJ, Osendarp SJM, Khatun F, Huda SN, Grantham-McGregor. Randomized controlled trial of the effect of zinc supplementation on the mental development of Bangladeshi infants. *Am J Clin Nutr.* 2001;74:381-6.
 68. Osendarp S, Santosham M, Black RE, Wahed MA, van Raaij JMA, Fuchs GJ. Effect of zinc supplementation between 1 and 6 mo of life on growth and morbidity of Bangladeshi infants in urban slums. *Am J Clin Nutr.* 2002;76:1401-8.
 69. Owusu-Ageyi S, Newton S, Mahama E, Febir LG, Ali M, Adjei K, *et al.* Impact of vitamin A with zinc supplementation on malaria morbidity in Ghana. *Nutrition J.* 2013;12:131.
 70. Penny ME, Marin RM, Duran A, Peerson JM, Lanata CF, Lönnerdal B, *et al.* Randomized controlled trial of the effect of daily supplementation with zinc or multiple micronutrients on the morbidity, growth, and micronutrient status of young Peruvian children. *Am J Clin Nutr.* 2004;79:457-65.
 71. Penny ME, Peerson JM, Marin RM, Duran A, Lanata CF, Lönnerdal B, *et al.* Randomised community based trial of the effect of zinc supplementation, with and without other micronutrients, on the duration of persistent childhood

- diarrhea in Lima, Peru. *J Pediatr.* 1999;135:208-17.
72. Radhakrishna KV, Hemalatha R, Geddam JJB, Kumar PA, Balakrishna N, Shatrugna V. Effectiveness of zinc supplementation to full term normal infants: A community based double blind, randomized, controlled, clinical trial. *PLoS One.* 2013;8:e61486.
 73. Rahman MM, Tofail F, Wahed MA, Fuchs GJ, Baqui AH, Alvarez JO. Short-term supplementation with zinc and vitamin A has no significant effect on the growth of undernourished Bangladeshi children. *Am J Clin Nutr.* 2002;75:87-91.
 74. Ram Kumar TV, Ramji S. Effect of zinc supplementation on growth in very low birth weight infants. *J Trop Paediatr.* 2012;58:50-54.
 75. Bentley ME, Caulfield LE, Ram M, Santizo MC, Hurtado E, Rivera JA, *et al.* Zinc supplementation affects the activity patterns of rural Guatemalan infants. *J Nutr.* 1997;127:1333-8.
 76. Rivera JA, Ruel MT, Santizo MC, Lønnestad B, Brown KH. Zinc supplementation improves the growth of stunted rural Guatemalan infants. *J Nutr.* 1998;128:556-62.
 77. Ruel MT, Rivera JA, Santizo M, Lønnestad B, Brown KH. Impact of zinc supplementation on morbidity from diarrhea and respiratory infections among rural Guatemalan children. *Pediatrics.* 1997;99:808-13.
 78. Allen LH, Rosado JL, Casterline JE, López P, Muñoz E, Garcia OP, *et al.* Lack of hemoglobin response to iron supplementation in anemic Mexican preschoolers with multiple micronutrient deficiencies. *Am J Clin Nutr.* 2000;71:1485-94.
 79. Rosado JL, Lopez P, Mufioz E, Martinez H, Allen LH. Zinc supplementation reduced morbidity, but neither zinc nor iron supplementation affected growth or body composition of Mexican preschoolers. *Am J Clin Nutr.* 1997;65:13-9.
 80. Rosado JL. Separate and joint effects of micronutrient deficiencies on linear growth. *J Nutr.* 1999;129:531S-3S.
 81. Rosado JL, Caamaño MC, Montoya YA, de Lourdes Solano M, Santos JI, Long KZ. Interaction of zinc or vitamin A supplementation and specific parasite infections on Mexican infants' growth: a randomized clinical trial. *Eur J Clin Nutr.* 2009;63:1176-84.
 82. Ruz M, Castillo-Duran C, Lara X, Codoceo J, Rebolledo A, Atalah E. A 14-mo zinc-supplementation trial in apparently healthy Chilean preschool children. *Am J Clin Nutr.* 1997;66:1406-13.
 83. Sampaio DLB, Mattos APD, Rebeiro TCM, Liete ME, Cole CR, Costa-Ribeiro Jr H. [Zinc and other micronutrients supplementation through the use of sprinkles: impact on the occurrence of diarrhea and respiratory infections in institutionalized children] Article in Spanish. *J Pediatr. (Rio J)* 2013;89:286-93.
 84. Sanchez J, Villada OA, Rojas ML, Montaya L, Diaz A, Vargas C, *et al.* [Effect of zinc amino acid chelate and zinc sulfate in the incidence of respiratory infection and diarrhea among preschool children in child daycare centers]. Article in Spanish. *Biomédica.* 2014;34:79-91.
 85. Sempértegui F, Estrella B, Correa E, Aguirre L, Saa B, Torres M, *et al.* Effects of short-term zinc supplementation on cellular immunity, respiratory symptoms, and growth of malnourished Equadorian children. *Eur J Clin Nutr.* 1996;50:42-6.
 86. Shankar AH, Geston B, Baisor M, Paino J, Tamija S, Adiguma T, *et al.* The influence of zinc supplementation on morbidity due to *Plasmodium falciparum*: A randomized trial in preschool children in Papua New Guinea. *Am J Trop Med Hyg.* 2000;62:663-9.
 87. Shrivastava SP, Roy AK, Jana UK. Zinc supplementation in protein energy malnutrition. *Indian Pediatr.* 1993;30:779-82.
 88. Silva APR, Vitolo MR, Zara LF, Castro CF. [Effects of zinc supplementation on 1- to 5-year old children]. Article in Spanish. *J Pediatr. (Rio J)* 2006;82:227-31.
 89. No Authors Listed. Effect of provision of micronutrient supplementation on growth and morbidity among young children in Pakistan. *Arch Dis Child.* 2013;98:691.
 90. Soofi S, Cousens S, Iqbal SP, Akhund T, Khan J, Ahmed I, *et al.* Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: a cluster-randomised trial. *Lancet.* 2013;382:29-40.
 91. Sur D, Gupta DN, Mondal SK, Ghosh S, Manna B, Rajendran K, *et al.* Impact of zinc supplementation on diarrheal morbidity and growth pattern of low birth weight infants in Kolkata, India: A randomized, double-blind, placebo-controlled, community-based study. *Pediatrics.* 2003;112:1327-32.
 92. Siegel EH, Kordas K, Stoltzfus RJ, Katz J, Khatri SK, LeClerq SC, *et al.* Inconsistent effects of iron-folic acid and/or zinc supplementation on the cognitive development of infants. *J Health Popul Nutr.* 2011;29:593-604.
 93. Surkan PJ, Shankar M, Katz J, Siegel EH, LeClerq SC, Khatri SK, *et al.* Beneficial effects of zinc supplementation on head circumference of Nepalese infants and toddlers: a randomized controlled trial. *Eur J Clin Nutr.* 2012;66:836-42.
 94. Taneja S, Bhandari N, Rongsen-Chandola T, Mahalanabis D, Fontaine O, Bhan MK. Effect of zinc supplementation on morbidity and growth in hospital-born, low-birth-weight infants. *Am J Clin Nutr.* 2009;90:385-91.
 95. Taneja S, Strand TA, Sommerfelt H, Bahl R, Bhandari N. Zinc supplementation for four months does not affect growth in young North Indian children. *J Nutr.* 2010;140:630-4.
 96. Umeta M, West CE, Haidar J, Deurenberg P, Hautvast J. Zinc supplementation and stunted infants in Ethiopia: A randomized controlled trial. *Lancet.* 2000;255:2121-6.
 97. Vasudevan A, Shedurnikar N, Kotecha PV. Zinc supplementation in severe malnutrition. *Indian Pediatr.* 1997;34:236-8.
 98. Wuehler SE, Sempértegui F, Brown KH. Dose-response trial of prophylactic zinc supplements, with or without copper, in young Ecuadorian children at risk of zinc deficiency. *Am J Clin Nutr.* 2008;87:723-33.
 99. Yang YX, Han JH, Shao XP, He M, Bian LH, Wang Z, *et al.* Effect of micronutrient supplementation on the growth of preschool children in China. *Biomed Environ Sci.* 2002;15:196-202.


100. Zlotkin S, Arthur P, Schauer C, Antwi KY, Yeung G, Piekarz A. Home-fortification with iron and zinc sprinkles or iron sprinkles alone successfully treats anemia in infants and young children. *J Nutr.* 2003;133:1075-80.
 101. Imdad A, Bhutta ZA. Effect of preventive zinc supplementation on linear growth in children under 5 years of age in developing countries: A meta-analysis of studies for input to the lives saved tool. *BMC Public Health.* 2011;11:S22.
 102. Mayo-Wilson E, Junior JA, Imdad A, Dean S, Chan XHS, Chan ES, *et al.* Zinc supplementation for preventing mortality, morbidity, and growth failure in children aged 6 months to 12 years of age. *Cochrane Database Syst Rev.* 2014;5:CD009384.
 103. Liu E, Pimpin L, Shulkin M, Kranz S, Duggan CP, Mozaffarian D, *et al.* Effect of zinc supplementation on growth outcomes in children under 5 years of age. *Nutrients.* 2018;10: pii: E377. doi: 10.3390/nu10030377.
-



WEB FIG. 1 Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.



WEB FIG. 2 Risk of bias summary: review authors' judgements about each risk of bias item for each included study.



WEB FIG. 3 Funnel plots depicting publication bias related to effect of zinc supplementation on (a) length/height-for-age Z-score; (b) change in length/height-for-age Z-score; (c) endline length/height; and (d) change in endline length/height.

WEB APPENDIX 1 DETAILS OF DATABASE SEARCH

<i>Database</i>	<i>Date</i>	<i>Search Strategy</i>	<i>Number of references</i>
Medline	June 4, 2017	"Zinc"[Mesh] OR "Zinc Sulfate"[Mesh] OR "Zinc Compounds"[Mesh]) AND ("Clinical Trial" or "Controlled Clinical Trial" or "Randomized Controlled Trial" or "Pragmatic Clinical Trial"[MeSH Terms]) AND (((("Child, Preschool" or "Infant"[MeSH Terms])) OR (Child[Text Word] OR Children[Text Word] OR Infant[Text Word] OR Under-5 Children[Text Word])))	664
Web of Science (including BIOSIS Previews)	June 8, 2017	TOPIC: ("Zinc" OR "Zinc Supplement*") AND TOPIC: ("Child" OR "Children") AND TOPIC: ("Clinical Trial" or "Controlled Clinical Trial" or "Randomized Controlled Trial"); Timespan: All years; Search language=Auto	731
Cochrane Controlled Trials Register	June 8, 2017	"zinc compound" in Title, Abstract, Keywords or zinc in Title, Abstract, Keywords and "Clinical Trial" or "Controlled Clinical Trial" or "Randomized Controlled Trial" in Publication Type and "Child" OR "Children" in Title, Abstract, Keywords	798
Embase	June 8, 2017	"Zinc OR "Zinc Sulfate" OR "Zinc Compounds" (all fields): 206513 limit 1 to (controlled clinical trial and preschool child <1 to 6 years>): 241	241
IBIDS	June 9, 2017	("zinc"[MeSH Terms] OR "zinc"[All Fields]) AND "Child"[All Fields] AND dietsuppl[sb]:	1319

WEB APPENDIX 2 ASSUMPTIONS AND CALCULATIONS FOR IMPUTATION/INTERPRETATION OF DATA FROM STUDIES INCLUDED IN THE SYSTEMATIC REVIEW

Locks, *et al.* [57]

SDs derived from SEM

Means and SDs of Zn and Zn+MV combined as intervention, that for placebo and MV combined as control

Sampaio, *et al.* [83]

Data given as median and IQR; mean assumed to be the same as median

IQR=1.35 SD

Mozaraffi-Khosravi, *et al.* [64]

Data for boys and girls given separately. The means and SDs were combined for analysis

Brown, *et al.* [23]

Data for medicinal zinc and fortified zinc group combined for comparison with control

Garenne, *et al.* [43]

SDs calculated from means and *P* value

Means for boys and girls given separately, which were combined for analyses

de Romana, *et al.* [31]

Data for 3 mg and 9 mg zinc group combined as intervention

Lind, *et al.* [53]

Data for Fe+ Zn and Zn groups combined as intervention group; and placebo and Fe groups as control

Sur, *et al.* [91]

Change in weight and length for intervention and control groups mentioned in text without SD with *P* < 0.001. *P* value was assumed to be equal to 0.001 and SD estimated accordingly

Yang, *et al.* [99]

Means for Zn and ZnCaVa combined as intervention; control and CaVa as control

Rosado, *et al.* [79]

SE converted to SD

Data for Fe+ Zn and Zn groups combined as intervention group; and placebo and Fe groups as control

GERA *et al.*

ZINC SUPPLEMENTATION AND GROWTH

Lira, *et al.* [55]

Data from 1 mg and 5 mg zinc combined as intervention group

Vasudevan, *et al.* [97]

P mentioned as >0.1, assumed to be 0.11 and SDs calculated from that.

Ruz, *et al.* [82]

For change in length means and SDs of children with different baseline HAZ given, which were combined to estimate the ones for the entire intervention and control group

Change in HAZ, WAZ and WLZ given as figures with exact *P* values. The means were estimated from the figures and then the SDs calculated from the *P* value

Dirren, *et al.* [37]

Data given as means and SEM from which SDs were derived

Data given separately for boys and girls, which was combined

Hong, *et al.* [51]

Data for boys and girls given separately; combined for analysis.

WEB APPENDIX 3 SUMMARY OF FINDINGS TABLES

A. Effect of Zinc Supplementation on Length/Height						
Patient or population: Children under 5 years						
Settings: Low and Middle Income Countries						
Intervention: Zinc Supplementation versus No supplementation						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Zinc versus No Zinc				
Length/Height for Age Z score (LAZ/HAZ)		The mean LAZ/HAZ in the intervention groups was 0 higher (0.07 lower to 0.07 higher)		9165 (25 studies)	⊕⊕⊕⊖ moderate ¹	Probably leads to little or no difference in endline HAZ score. Among five additional trials not included in meta-analysis, three reported no significant difference while 2 reported higher HAZ with Zinc supplementation.
Change in LAZ/HAZ		The mean change in LAZ/HAZ in the intervention groups was 0.11 higher (-.0.0 to 0.21 higher)		8852 (13 studies)	⊕⊕⊕⊖ moderate ²	Probably leads to little increase in change in HAZ score.
Length/Height (cm)		The mean length/height in the intervention groups was 1.18 cm higher (0.63 lower to 2.99 higher)		6303 (19 studies)	⊕⊕⊕⊖ moderate ³	Probably leads to little or no difference in endline length or height. Two additional trials, not included in the meta-analysis reported no significant difference in endline length/height.
Change in Length (cm)		The mean change in length in the intervention groups was 0.43 cm higher (0.16 to 0.7 higher)		10783 (25 studies)	⊕⊕⊕⊕ high	Results in little increase in change in length.

% Height for Age		The mean % height for age in the intervention groups was 1.9 % higher (1.01 to 2.79 % higher)		57 (1 study)	⊕⊖⊖⊖ very low ^{4,5}	It is uncertain whether Zinc supplementation increases height for age % because the certainty of the evidence is very low
Change in % Height for Age		The mean change % height for age in the intervention groups was 2.24% higher (1.56 to 2.92 % higher)		57 (1 study)	⊕⊖⊖⊖ very low ^{4,5}	It is uncertain whether Zinc supplementation increases height for age % change because the certainty of the evidence is very low
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval;</p> <p>GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.</p>						

¹ Downgraded by 1 for serious risk of bias. 15 trials had high risk of bias for attrition, 5 for other bias and one for baseline incomparability between clusters.

² Downgraded by 1 for serious risk of bias. 5 trials had unclear risk of bias for allocation concealment and blinding for outcome assessment, 5 were at high risk of bias for attrition

³ Downgraded by 1 for serious risk of bias. Several trials were at high risk: one for random sequence generation, two for allocation concealment, two for blinding, 12 for attrition, 3 for other bias and one for baseline comparability of clusters.

⁴ Downgraded by 2 for very serious indirectness. Only one trial with a small population from urban India the findings of which cannot be extrapolated to other countries and settings.

⁵ Downgraded by 1 for imprecision; small sample size with wide 95% CI around the effect estimate.

B. Effect of Zinc Supplementation on Weight						
Patient or population: Children under 5 years						
Settings: Low and Middle Income Countries						
Intervention: Zinc Supplementation versus No supplementation						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Zinc Supplementation versus No supplementation				
Weight for age Z score (WAZ)		The mean WAZ in the intervention groups was 0.05 Z higher (0.03 lower to 0.13 higher)		9033 (23 studies)	⊕⊕⊕⊖ moderate ¹	Probably leads to little or no difference in endline WAZ score. Two additional trials also did not document any significant difference in WAZ in the Zinc supplemented group
Change in WAZ		The mean change in waz in the intervention groups was 0.03 higher (0.01 lower to 0.08 higher)		8851 (13 studies)	⊕⊕⊕⊖ moderate ²	Probably leads to little or no difference in change in WAZ score.
Weight (kg)		The mean weight in the intervention groups was 0.23 kg higher (0.03 to 0.42 higher)		6293 (19 studies)	⊕⊕⊕⊖ moderate ³	Probably leads to little increase in weight
Change in weight (kg)		The mean change in weight in the intervention groups was 0.11 kg higher (0.05 to 0.17 higher)		10143 (23 studies)	⊕⊕⊕⊖ moderate ⁴	Probably leads to little increase in change in weight
Rate of weight gain (g/kg/day)		The mean rate of weight gain in the intervention groups was 1.52 g/kg/day higher (0.62 lower to 3.65 higher)		114 (2 studies)	⊕⊖⊖⊖ very low ^{5,6,7}	It is uncertain whether Zinc supplementation increases rate of weight gain because the certainty of the evidence is very low
% Weight for age		The mean % weight for age in the intervention groups		57 (1 study)	⊕⊖⊖⊖ very low ^{7,8}	It is uncertain whether Zinc supplementation increases weight for age % because the certainty

		was 3.9 higher (1.72 to 6.08 higher)				of the evidence is very low
Change % Weight for Age		The mean change % weight for age in the intervention groups was 3.2 higher (1.27 to 5.13 higher)	57 (1 study)	⊕⊖⊖⊖ very low ^{7,8}		It is uncertain whether Zinc supplementation increases weight for age % change because the certainty of the evidence is very low
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval;</p> <p>GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.</p>						

¹ Downgraded by 1 for serious risk of bias. 14 trials had high risk of attrition bias, 4 had high risk of other bias and there was baseline imbalance in one cluster RCT

² Downgraded by 1 for serious risk of bias, 5 trials were at high risk of bias for attrition and 2 for other bias.

³ Downgraded by 1 for serious risk of bias, 2 trials were at high risk for random sequence generation, 3 for allocation concealment, 2 for blinding, 12 for attrition, 2 for other bias and one for baseline comparability between clusters

⁴ Downgraded by 1 for serious risk of bias, One trial was at high risk of bias for random sequence generation, one for allocation concealment, one for blinding, 11 for attrition and two for other bias

⁵ Downgraded by 1 for serious risk of bias. Of the two included trials one was at high risk for random sequence generation and allocation concealment and the other had unclear risk of bias for random sequence generation, allocation concealment and blinding

⁶ Downgraded by 1 for indirectness. Both trials from urban India with small datasets the conclusions of which cannot be extrapolated to other populations and settings

⁷ Downgraded by 1 for imprecision. Small sample size with wide 95% CI around the effect estimate

⁸ Downgraded by 2 for serious indirectness. Only one trial with a small population from urban India the findings of which cannot be extrapolated to other countries and settings.

C. Effect of Zinc Supplementation on Weight-for-Height and Mid Upper Arm Circumference						
Patient or population: Children under 5 years						
Settings: Low and Middle Income Countries						
Intervention: Zinc Supplementation versus No supplementation						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Zinc Supplementation versus No supplementation				
Weight for Height Z score (WHZ)		The mean WHZ in the intervention groups was 0.03 Z higher (0.02 lower to 0.08 higher)		8392 (19 studies)	⊕⊕⊕⊖ moderate ¹	Probably leads to little or no difference in endline WHZ score. Three additional trials also did not document any significant difference in WHZ in the Zinc supplemented group
Change in WHZ		The mean change in WHZ in the intervention groups was 0.01 Z higher (0.03 lower to 0.04 higher)		8706 (12 studies)	⊕⊕⊕⊖ moderate ²	Probably leads to little or no difference in change in WHZ score.
% Weight for Height		The mean % weight for height in the intervention groups was 0.7% higher (0.81 lower to 2.21 higher)		57 (1 study)	⊕⊖⊖⊖ very low ^{3,4}	It is uncertain whether Zinc supplementation increases weight for height % because the certainty of the evidence is very low
Change % Weight for Height		The mean change % weight for height in the intervention groups was 1.17% higher (0.09 lower to 2.43 higher)		57 (1 study)	⊕⊖⊖⊖ very low ^{3,4}	It is uncertain whether Zinc supplementation increases weight for height % because the certainty of the evidence is very low
Mid Upper Arm Circumference (MUAC; cm)		The mean MUAC in the intervention groups was 0 cm higher (0.08 lower to 0.09 higher)		4236 (7 studies)	⊕⊕⊕⊖ moderate ⁵	Probably leads to little or no difference in endline Mid Upper Arm Circumference.
Change in MUAC		The mean change in MUAC		1724	⊕⊕⊕⊖	Probably leads to little increase in Mid

(cm)	(cm) in the intervention groups was 0.09 cm higher (0.01 to 0.16 higher)		(8 studies)	moderate ⁶	Upper Arm Circumference change.
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval;</p>					
<p>GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.</p>					

¹ Downgraded by 1 for serious risk of bias. 12 trials were at high risk of bias for attrition, 4 for other bias and one for baseline incomparability between clusters.

² Downgraded by 1 for serious risk of bias. 5 trials were at high risk of bias for attrition and 2 for other bias

³ Downgraded by 2 for very serious indirectness. Only one trial with a small population from urban India, the findings of which cannot be extrapolated to other countries and settings.

⁴ Downgraded by 1 for imprecision; small sample size with wide 95% CI around the effect estimate

⁵ Downgraded by 1 for serious risk of bias. One trial was at high risk of bias for random sequence generation and allocation concealment, 5 for attrition and 2 for other bias.

⁶ Downgraded by 1 for serious risk of bias. One trial was at high risk of bias for random sequence generation and allocation concealment, 2 for attrition and one for other bias.

D. Effect of Zinc Supplementation on Head Circumference, Stunting, Underweight and Wasting						
Patient or population: Children under 5 years						
Settings: Low and Middle Income Countries						
Intervention: Zinc Supplementation versus No supplementation						
Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Zinc Supplementation versus No supplementation				
Head Circumference (cm)		The mean head circumference in the intervention groups was 0.39 cm higher (0.03 to 0.75 higher)		2966 (6 studies)	⊕⊕⊕⊖ ¹ moderate	Probably leads to little increase in head circumference
Change in Head Circumference (cm)		The mean change in head circumference in the intervention groups was 0.26 cm higher (0.18 lower to 0.71 higher)		497 (4 studies)	⊕⊕⊕⊖ ² moderate	Probably leads to little or no difference in change in head circumference
Change in head circumference z score (Z)		The mean change in head circumference z score in the intervention groups was 0.12 higher (0.11 to 0.13 higher)		569 (1 study)	⊕⊕⊖⊖ ³ low	May leads to little increase in change in head circumference
Stunting	Study population		RR 1 (0.95 to 1.06)	11838 (9 studies)	⊕⊕⊕⊖ ⁴ moderate	Probably leads to little or no difference in stunting
	stunting327 per 1000	327 per 1000 (310 to 346)				
	Moderate					
	281 per 1000	281 per 1000 (267 to 298)				
Underweight	Study population		RR 0.94 (0.82 to 1.06)	8988 (7 studies)	⊕⊕⊕⊖ ⁵ moderate	Probably leads to little or no difference in underweight
	331 per 1000	311 per 1000 (271 to 351)				
	Moderate					
	395 per 1000	371 per 1000 (324 to 419)				

Wasting	Study population		RR 1.08 (0.96 to 1.21)	8677 (7 studies)	⊕⊕⊕⊖ moderate ⁵	Probably leads to little or no difference in wasting
	168 per 1000	182 per 1000 (161 to 203)				
	Moderate					
	135 per 1000	146 per 1000 (130 to 163)				
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio;</p> <p>GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.</p>						

¹ Downgraded by 1 for serious risk of bias. All included trials were at high risk of bias for attrition, one for blinding, one for attrition and one for baseline incomparability between clusters

² Downgraded by 1 for serious risk of bias. Three trials were at high risk of bias for attrition and one for other bias.

³ Downgraded by 2 for very serious risk of bias. Only one trial from rural Nepal the findings of which cannot be extrapolated to other settings or populations.

⁴ Downgraded by 1 for serious risk of bias. 4 trials were at high risk of bias for attrition, one for other bias and one for baseline incomparability between clusters.

⁵ Downgraded by 1 for serious risk of bias. Three trials were at high risk of bias for attrition, one for other bias and one for baseline incomparability between clusters.

WEB TABLE I CHARACTERISTICS OF INCLUDED STUDIES

Study [Ref.]; Country	Zinc Salt	Intervention	Comparator	Initial age (mo)	Participants (n) (Test/Control)	Dose (mg or *mg/kg)	Duration (mo)	Baseline zinc level (mcg/dL)	Baseline HAZ	Baseline Stunting (%)	Outcomes
Hess, <i>et al.</i> [48]; Burkina Faso	Zinc sulfate	LNS+Zn	LNS+placebo	9	1833/602	5, 10	9	69.5	-1.21	21.9	Weight, Length, HC, MUAC, LAZ, WAZ, Stunting, Underweight, Wasting
Locks, <i>et al.</i> [57]; Tanzania	Zinc sulfate	Zn+MV Zinc	MV Placebo	1.5 -19	1198/1202	5-10	18	Not mentioned	-0.28	Not mentioned	Change in HAZ, WAZ, WHZ, Stunting, wasting, underweight
Mathur, <i>et al.</i> [62]; India	Zinc gluconate	Zn+MV	Multivitamins	0	50/50	2*	3	Not mentioned	Not mentioned	Not mentioned	Weight, Length, HC
Becquey, <i>et al.</i> [16]; Burkina Faso	Zinc sulfate	Zinc	No intervention	6-27	391/962	7	11	67	-1.22	28.6	Change in Weight, Length, WAZ, HAZ, WLZ, Wasting, underweight and stunting
El Farghali, <i>et al.</i> [38]; Egypt	Zinc sulfate	Zinc	Placebo	0	108/92	10	6	111.35	Not mentioned	Not mentioned	Weight, Length, MUAC, HC
Sanchez <i>et al.</i> [84]; Colombia	Zinc sulfate,	Zinc	Placebo	24-60	205/96	7	4	Not mentioned	Not mentioned	5	Weight, Height, BMI
Colombo, <i>et al.</i> [30]; Peru	Zinc sulfate	Zn + Iron + Copper	Iron+ copper	6	129/122	10	12	93.17	-0.55	Not mentioned	WAZ, LAZ
Adriani, <i>et al.</i> [12]; Indonesia	Zinc sulfate (Zn + vitamin A)	Zinc+Vitamin A	vitamin A+placebo	48-60	12/12	0.9	6	35	-2	100	HAZ
Abdollahi, <i>et al.</i> [11]; Iran	Zinc sulfate	Zinc	Placebo	6-24	291/302	5	3	Not mentioned	Not mentioned	Not mentioned	Weight, Height
Soofi, <i>et al.</i> [90]; Pakistan	Zinc gluconate	Zinc + micronutrient powder	Micronutrient powder	6	830/784	10	12	84	Not mentioned	Not mentioned	Wasting, stunting, underweight, length
Sampaio, <i>et al.</i> [83];	Zinc gluconate	Sprinkles with Zinc	Sprinkles without zinc	6-48	75/68	5	3	Not mentioned	-0.41	Not mentioned	WAZ, LAZ, WHZ

Brazil												
Radhakrishna, <i>et al.</i> [72]; India	Zinc sulfate	Zn+riboflavin	Riboflavin	4	154/147	5	14	Not mentioned	Not mentioned	Not mentioned	Wasting, stunting, underweight, length, weight, WAZ, HAZ, WHZ	
Owusu-Ageyi, <i>et al.</i> [69]; Ghana	Zinc gluconate	Zinc+Vitamin A	vitamin A+placebo	6-24	100/100	10	6	69	-1	32	Weight, Height, WAZ, HAZ, WHZ	
Olney, <i>et al.</i> [65]; Zanzibar	Zinc sulfate	Zn+Iron Zinc	Iron Placebo	1-35	247	10	12	Not mentioned	Not mentioned	30	HAZ	
Surkan, <i>et al.</i> [93]; Nepal	Zinc sulfate	Zinc+iron+folic acid Zinc	Iron+folic acid Placebo	4-17	288/281	5	12	Not mentioned	Not mentioned	22	Change in HC z score	
Ram Kumar, [74]; <i>et al.</i> India	Zinc sulfate	Zinc	Placebo	0	36/27	10	2	Not mentioned	Not mentioned	Not mentioned	Weight, Length, HC	
Aminisani, <i>et al.</i> [14]; Iran	Zinc sulfate	Zinc	Placebo	0-1	40/36	5	6	Not mentioned	Not mentioned	Not mentioned	Change in weight, height and HC	
Taneja, <i>et al.</i> [95]; India	Zinc gluconate	Zinc	Placebo	6-30	1093/1133	10-20	4	80.4	-1.79	Not mentioned	Change in weight, height, WAZ, LAZ, WHZ	
Islam, <i>et al.</i> [52]; Bangladesh	Zinc sulfate	Zinc+MV	MV	0-1	50/50	3	1.5	62.1	Not mentioned	Not mentioned	Weight, Length, HC	
Chhagan, <i>et al.</i> [27]; South Africa	Zinc gluconate	Zinc+Vitamin A	Vitamin A	6	123/124	10	18	Not mentioned	-0.64	18.60	LAZ	
Fischer Walker, <i>et al.</i> [41]; Bangladesh	Zinc acetate	Zinc+iron Zinc + riboflavin	Iron Riboflavin	6	276/290	20	6	55.1	-1.2	Not mentioned	Weight, Height, MUAC	
Taneja, <i>et al.</i> [94]; India	Zinc sulfate	Zinc	Placebo	0-1	1026/1026	5-10	12	64	Not mentioned	Not mentioned	Weight, Length, Wasting, Stunting, Underweight	
Rosado, <i>et al.</i> [80]; Mexico	Zinc Methionine	Zinc+Vitamin A Zinc	Vitamin A Placebo	5-24	395/391	20	12	Not mentioned	-0.97	19	HAZ	
Mozaraffi-Khosravi, <i>et al.</i> [64]; Iran	Zinc sulfate	Zinc	Placebo	24-60	40/45	5	6	Not mentioned	-1.65	20	Weight, Height, MUAC, Wasting, Stunting	
Wuehler, <i>et</i>	Zinc sulfate	Zinc	Placebo	10-30	313/108	3-10	6	70.8	-2.3	60	Change in weight, length,	

<i>al.</i> [98]; Ecuador											WAZ, WLZ, HAZ
Dijkhuizen, <i>et al.</i> [33]; SE Asia	Zinc sulfate	Zinc+Iron Zinc	Iron Placebo	4-6	1246/1205	10	6	113.5	-0.83	7.30	WAZ, HAZ, WLZ, Stunting, Change in weight and length
Brown, <i>et al.</i> [23] Peru	Zinc sulfate [#]	Zinc+MV	MV	5-7	168/94	3	6	77.6	-1.19	Not mentioned	Change in weight, length, WAZ, WLZ, HAZ
Long, <i>et al.</i> [58]; Mexico	Zinc Methionine	Zinc+Vitamin A	Vitamin A+placebo	6-15	364/343	20	12	Not mentioned	Not mentioned	10	Stunting
Garenne, <i>et al.</i> [43]; Burkina Faso	Zinc sulfate	Zinc	Placebo	6-30	342/344	12.5	6	99.1	-1.59	Not mentioned	Change in Weight Height MUAC
Fahmida, <i>et al.</i> [40]; Indonesia	Zinc sulfate	Zinc	Placebo	3-6	192/199	10	6	129.6	-1.01	15.50	Wasting, stunting, underweight, WAZ, HAZ, WLZ
Silva, <i>et al.</i> [88]; Brazil	Zinc sulfate	Zinc	Placebo	12-59	28/30	10	4	56.5	-1.9	Not mentioned	WHZ, HAZ
de Romana, <i>et al.</i> [31]; Peru	Zinc sulfate [#]	Zinc+iron	Iron	36-48	22/12	10	2.5	75	-2.67	100	Weight. Height, HAZ, WAZ, WHZ
Gardner, <i>et al.</i> [42]; Jamaica	Zinc sulfate	Zinc Zinc + stimulation	No intervention Stimulation	9-30	55/59	10	6	Not mentioned	-1.42	Not mentioned	Weight. Height, HAZ, WAZ, WHZ
Brooks, <i>et al.</i> [20]; Bangladesh	Zinc acetate	Zinc	Placebo	2-12	329/309	5	10	Not mentioned	Not mentioned	Not mentioned	Weight, Height
Penny, <i>et al.</i> [70]; Peru	Zinc gluconate	Zinc	Placebo	6-36	71/75	10	6	70.3	-1.56	32	Change in length, weight, LAZ, WAZ and MUAC
Lind, <i>et al.</i> [53]; Indonesia	Zinc sulfate	Zinc+Iron Zinc	Iron Placebo	6	323/327	10	6	Not mentioned	-0.34	3.50	WAZ, WHZ, HAZ, MUAC
Black, <i>et al.</i> [18]; India	Zinc sulfate	Zn + Micronutrient + Riboflavin	Micronutrient +Riboflavin	1	79/71	5	9	Not mentioned	Not mentioned	Not mentioned	Change in weight, length; HAZ, WHZ
Alarcon, <i>et al.</i> [13]; Peru	Zinc sulfate	Zn + Iron + vitamin A	Iron+Vitamin A+placebo	6-35	109/104	7	4.5	Not mentioned	-1.04	Not mentioned	Weight, height, WAZ, HAZ, WHZ, change in Weight, height, WAZ, HAZ, WHZ
Zlotkin, <i>et al.</i> [100]; Ghana	Zinc gluconate	Zn + Iron + vitamin C	Iron+Vitamin C	6-18	124/115	10	2	120.3	-1.76	Not mentioned	WAZ, HAZ, WHZ

Sur, <i>et al.</i> [91]; India	Zinc sulfate	Zn+vitamin B-complex	Vitamin B-complex	7 d	50/50	5	12	Not mentioned	Not mentioned	Not mentioned	Change in weight, length; WAZ
Makonnen, <i>et al.</i> [60]; South Africa	Zinc sulfate	Zinc	Placebo	6-60	138/116	10	3	Not mentioned	Not mentioned	Not mentioned	Underweight
Yang, <i>et al.</i> [99]; China	Zinc sulfate	Zinc Zn+calcium+vitamin A	No intervention Calcium+vitamin A	36-60	60/56	3.5	12	Not mentioned	Not mentioned	Not mentioned	Change in weight, length
Rahman, <i>et al.</i> [73]; Bangladesh	Zinc sulfate	Zin+Vitamin A Zinc	Vitamin A Placebo	12-35	336/317	20	0.5	Not mentioned	-2.41	Not mentioned	Change in weight, length, WAZ, WLZ, HAZ
Osendarp, <i>et al.</i> [68]; Bangladesh	Zinc acetate	Zinc	Placebo	1	138/133	5	5	99.9	-1.1	Not mentioned	Weight, Length, WAZ, HAZ, WLZ, Change in weight, length, HC, MUAC
Castillo Duran, <i>et al.</i> [26]; Chile	Zinc sulfate	Zinc	Placebo	17-19	21/21	5	12	Not mentioned	Not mentioned	Not mentioned	Weight, Length
Castillo Duran, <i>et al.</i> [25]; Chile	Zinc sulfate	Zinc	Placebo	0.6	57/55	5	12	Not mentioned	Not mentioned	Not mentioned	WAZ, HAZ, WLZ
Umeta, <i>et al.</i> [96]; Ethiopia	Zinc sulfate	Zinc	Placebo	6-12	92/92	10	6	Not mentioned	-1.72	50	Change in weight, length, WAZ, WLZ, HAZ
Shankar, <i>et al.</i> [86]; Papua New Guinea	Zinc gluconate	Zinc	Placebo	6-60	103/109	10	10.5	70	-1.9	Not mentioned	WAZ, HAZ, MUAC
Elizabeth, <i>et al.</i> [39]; India	Not mentioned	Zinc + MV	MV	1-60	29/28	2*	3	49.8	Not mentioned	93	% weight for height, weight for age, height for age; change in % weight for height, weight for age, height for age
Rosado, <i>et al.</i> [79]; Mexico	Zinc Methionine	Zinc+Iron Zinc	Iron Placebo	18-36	97/97	20	12	Not mentioned	-1.6	36.5	Change in weight, height, WAZ, HAZ, WHZ
Hershkovitz, <i>et al.</i> [46]; Israel	Zinc acetate	Zinc	Placebo	3-9	14/11	2*	3	Not mentioned	-1.6	15	WAZ, LAZ, HAZ

Rivera, <i>et al.</i> [76]; Guatemala	Zinc sulfate	Zinc	Placebo	6-9	45/44	10	7	Not mentioned	-2.15	Not mentioned	Weight, height, MUAC, WAZ, LAZ, HAZ; Change in Weight, height, MUAC, WAZ, LAZ, HAZ
Meeks Gardner, <i>et al.</i> [63]; Jamaica	Zinc sulfate	Zinc	Placebo	6-24	31/30	5	3	Not mentioned	-2.85	100	Change in weight, length, HC
Lira, <i>et al.</i> [55]; Brazil	Zinc sulfate	Zinc	Placebo	0	112/54	1, 5	6	Not mentioned	Not mentioned	Not mentioned	Change in weight, length
Vasudevan, <i>et al.</i> [97]; India	Zinc sulfate	Zinc	Placebo	8-24	31/31	20	3	98.4	Not mentioned	Not mentioned	Rate of weight gain
Ruz, <i>et al.</i> [82]; Chile	Zinc sulfate	Zinc	Placebo	27-50	27/26	10	14	144	-0.52	Not mentioned	Change in length, WAZ, HAZ, WLZ
Sempertegui, <i>et al.</i> [15]; Ecuador	Zinc sulfate	Zinc	Placebo	12-59	25/25	10	2	86.5	-2	94	WAZ, HAZ
Ninh, <i>et al.</i> [3]; Vietnam	Zinc sulfate	Zinc	Placebo	4-36	/73/73	10	5	Not mentioned	-2.9	100	Weight, Height, WAZ, HAZ, WHZ
Castillo Duran, <i>et al.</i> [24]; Chile	Zinc acetate	Zinc	Placebo	0	35/33	3	6	104.2	-1.3	Not mentioned	Length, WAZ, HAZ, WHZ, HC
Dirren, <i>et al.</i> [37];	Zinc sulfate	Zinc	Placebo	12-50	48/48	10	15	73.5	-2.87	Not mentioned	Change in weight, height, WAZ, HAZ, WHZ
Shrivastava, <i>et al.</i> [87]; India	Zinc sulfate	Zinc+MV	MV	8-24	26/26	22.5	3	89.3	Not mentioned	Not mentioned	Weight, Rate of weight gain
Bates, <i>et al.</i> [15]; Gambia	Zinc gluconate	Zinc	Placebo	7-28	56/56	20	15	128.7	Not mentioned	Not mentioned	Weight, Length, MUAC; Change in Weight, Length, MUAC
Hong, <i>et al.</i> [51]; China	Zinc sulfate	Zinc+Vitamin B	Vitamin B	0	32/33	1.1-2.2*	6	111	Not mentioned	Not mentioned	Change in weight, length

[#]Used fortification as a strategy for zinc supplementation

Zn: Zinc; MV: Multivitamin; HC: head circumference; WAZ: weight-for-age Z-score; HAZ: height-for-age Z-score; LAZ: length-for-age Z-score; WHZ: weight-for-height Z-score; WLZ: weight-for-length Z-score MUAC: mid upper arm circumference.